Randomized, Double-Blind, Safety and Efficacy Study of RE-021 (Sparsentan) in Focal Segmental Glomerulosclerosis
Clinical trial NCT01613118 · COMPLETED
Trial details
- NCT number
- NCT01613118
- Sponsor
- Travere Therapeutics, Inc.
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-03-01
- Primary completion
- 2016-06-01
- Enrollment
- 109
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.